Companies in #Solid Tumor Immunotherapy
Found 2 companies operating in this sector.
TScan Therapeutics is a clinical-stage immunotherapy company developing a portfolio of TCR-T cell therapies for hematologic malignancies and solid tumors. The company's lead program TSC-101 is in the ALLOHA Phase 1 study for patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation, with positive initial data from Cohort C reported in 2026 showing 11 of 14 dosed patients achieving complete donor chimerism. TScan is preparing TSC-101 for a planned Phase 3 study in blood cancers as the next value-driving event. The company has also established a Cellares automated-manufacturing agreement for TSC-101 production scalability. TScan is headquartered in Waltham, Massachusetts and trades on the Nasdaq Capital Market under the symbol TCRX.
Tvardi Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of STAT3 inhibitors for cancer and inflammatory diseases. The company's lead candidate TTI-101 is an oral small-molecule STAT3 inhibitor; TTI-109 is a phosphate prodrug of TTI-101 designed to improve oral bioavailability while preserving target engagement. The Phase 1 study of TTI-109 announced July 7, 2026 confirmed rapid prodrug conversion to TTI-101 within two hours, dose-proportional pharmacokinetics with plasma levels above the STAT3 IC50, and reductions of up to 60% in STAT3-driven immune cell populations across Th17, Tfh, and B cell subsets in an exploratory pharmacodynamic analysis. Planned Phase 2 initiation in hepatocellular carcinoma and other STAT3-driven indications is the next value-driving event. Tvardi is headquartered in Houston, Texas and trades on the Nasdaq Capital Market under the symbol TVRD.